Monkasta (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1 on airway cells. By preventing leukotriene D4 from binding, it stops the inflammatory cascade that causes bronchoconstriction, mucus production, and swelling, thereby helping keep the airways open and reducing allergic inflammation.

The appropriate dose of Monkasta is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Dosage recommendations are provided in the product label and should be followed exactly as directed by the prescriber.

Safety data for montelukast in pregnancy are limited, so the drug should only be used if the potential benefit justifies any potential risk to the fetus. During breastfeeding, montelukast does pass into milk in small amounts; clinicians should weigh the benefits to the mother against possible effects on the infant.

To request Monkasta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Monkasta (montelukast) belongs to the leukotriene receptor antagonist class, which is taken orally and complements inhaled corticosteroids or bronchodilators. Compared with inhaled steroids, it offers a systemic option for patients who have difficulty using inhalers, but it is generally less potent for acute symptom relief and is used mainly for maintenance therapy.

Monkasta tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

Monkasta is taken orally as a tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food. Consistency in the time of day helps maintain steady drug levels, and patients should follow the schedule prescribed by their clinician.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, mood changes including depression or suicidal thoughts, and rare skin conditions like Stevens‑Johnson syndrome. Any sudden psychiatric symptoms, rash, or signs of liver injury should prompt immediate medical evaluation.

Monkasta is contraindicated in patients with known hypersensitivity to montelukast or any component of the tablet. Caution is advised for individuals with severe hepatic impairment, and it should be avoided in patients who have experienced serious hypersensitivity reactions to other leukotriene receptor antagonists.